Cargando…
Dual inhibition of IL-17A and IL-17F in psoriatic disease
Psoriasis and psoriatic arthritis are chronic immune-mediated disorders with involvement of interleukin (IL)-17 cytokines in their pathogenesis. IL-17A has been considered to be the most biologically active, but IL-17F is also over-expressed in skin and synovial tissues of patients with these diseas...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366125/ https://www.ncbi.nlm.nih.gov/pubmed/34408825 http://dx.doi.org/10.1177/20406223211037846 |
_version_ | 1783738847600836608 |
---|---|
author | Iznardo, Helena Puig, Lluís |
author_facet | Iznardo, Helena Puig, Lluís |
author_sort | Iznardo, Helena |
collection | PubMed |
description | Psoriasis and psoriatic arthritis are chronic immune-mediated disorders with involvement of interleukin (IL)-17 cytokines in their pathogenesis. IL-17A has been considered to be the most biologically active, but IL-17F is also over-expressed in skin and synovial tissues of patients with these diseases. Many therapeutic advances have been made in the past years, but some needs remain unmet. Dual inhibitor and bispecific antibodies simultaneously targeting IL-17A and IL-17F could provide better disease control. Herein we review current evidence on bimekizumab and sonelokimab. The antigen-binding site of bimekizumab neutralizes both IL-17A and IL-17F; phase I, II, and III studies have demonstrated its efficacy and safety in psoriasis and psoriatic arthritis. Sonelokimab is a trivalent nanobody targeting IL-17A and IL-17F; phase I and II studies with this molecule have yielded promising results in psoriasis. |
format | Online Article Text |
id | pubmed-8366125 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-83661252021-08-17 Dual inhibition of IL-17A and IL-17F in psoriatic disease Iznardo, Helena Puig, Lluís Ther Adv Chronic Dis Review Psoriasis and psoriatic arthritis are chronic immune-mediated disorders with involvement of interleukin (IL)-17 cytokines in their pathogenesis. IL-17A has been considered to be the most biologically active, but IL-17F is also over-expressed in skin and synovial tissues of patients with these diseases. Many therapeutic advances have been made in the past years, but some needs remain unmet. Dual inhibitor and bispecific antibodies simultaneously targeting IL-17A and IL-17F could provide better disease control. Herein we review current evidence on bimekizumab and sonelokimab. The antigen-binding site of bimekizumab neutralizes both IL-17A and IL-17F; phase I, II, and III studies have demonstrated its efficacy and safety in psoriasis and psoriatic arthritis. Sonelokimab is a trivalent nanobody targeting IL-17A and IL-17F; phase I and II studies with this molecule have yielded promising results in psoriasis. SAGE Publications 2021-08-12 /pmc/articles/PMC8366125/ /pubmed/34408825 http://dx.doi.org/10.1177/20406223211037846 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Iznardo, Helena Puig, Lluís Dual inhibition of IL-17A and IL-17F in psoriatic disease |
title | Dual inhibition of IL-17A and IL-17F in psoriatic disease |
title_full | Dual inhibition of IL-17A and IL-17F in psoriatic disease |
title_fullStr | Dual inhibition of IL-17A and IL-17F in psoriatic disease |
title_full_unstemmed | Dual inhibition of IL-17A and IL-17F in psoriatic disease |
title_short | Dual inhibition of IL-17A and IL-17F in psoriatic disease |
title_sort | dual inhibition of il-17a and il-17f in psoriatic disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366125/ https://www.ncbi.nlm.nih.gov/pubmed/34408825 http://dx.doi.org/10.1177/20406223211037846 |
work_keys_str_mv | AT iznardohelena dualinhibitionofil17aandil17finpsoriaticdisease AT puiglluis dualinhibitionofil17aandil17finpsoriaticdisease |